PXL 01

Drug Profile

PXL 01

Alternative Names: PXL-01

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaSurgics
  • Class Glycoproteins; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Post-surgical adhesions

Highest Development Phases

  • Phase II Post-surgical adhesions

Most Recent Events

  • 15 Feb 2018 Promore Pharma regains global manufacturing rights for PXL 01
  • 01 Feb 2018 Promore Pharma has patent protection for PXL 01 in Europe, South Africa and Australia
  • 01 Feb 2018 Promore Pharma has patent protection for PXL 01 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top